<DOC>
	<DOCNO>NCT00343915</DOCNO>
	<brief_summary>To evaluate persistence antibody hepatitis B 30 , 42 , 54 66 month first dose hepatitis B primary vaccination course . Subjects age 11 15 year time primary vaccination course . At time enrollment present long-term follow-up study subject age 13 18 year . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</brief_summary>
	<brief_title>Immuno &amp; Safety Study GSK Biologicals ' Thio Preservative Free Hepatitis B Vaccine Subjects Aged 11-15 Yrs</brief_title>
	<detailed_description>All subject participate primary study , receive either 2 3 dos GSK Biologicals hepatitis B vaccine , consent participate long-term follow-up Month 42 contact investigator . No additional subject recruit long-term follow-up study vaccine administer .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects participate primary study HBV280 Written inform consent obtain subject and/ parent guardian subject bloodsampling visit year</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Persistence</keyword>
	<keyword>Hepatitis B vaccine</keyword>
</DOC>